ORIGINAL RESEARCH ARTICLE

Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus
Results From the CANVAS Program

BACKGROUND: Canagliflozin is a sodium glucose cotransporter 2 inhibitor that reduces the risk of cardiovascular events. We report the effects on heart failure (HF) and cardiovascular death overall, in those with and without a baseline history of HF, and in other participant subgroups.

METHODS: The CANVAS Program (Canagliflozin Cardiovascular Assessment Study) enrolled 10 142 participants with type 2 diabetes mellitus and high cardiovascular risk. Participants were randomly assigned to canagliflozin or placebo and followed for a mean of 188 weeks. The primary end point for these analyses was adjudicated cardiovascular death or hospitalized HF.

RESULTS: Participants with a history of HF at baseline (14.4%) were more frequently women, white, and hypertensive and had a history of prior cardiovascular disease (all $P<0.001$). Greater proportions of these patients were using therapies such as blockers of the renin angiotensin aldosterone system, diuretics, and β-blockers at baseline (all $P<0.001$). Overall, cardiovascular death or hospitalized HF was reduced in those treated with canagliflozin compared with placebo (16.3 versus 20.8 per 1000 patient-years; hazard ratio [HR], 0.78; 95% confidence interval [CI], 0.67–0.91), as was fatal or hospitalized HF (HR, 0.70; 95% CI, 0.55–0.89) and hospitalized HF alone (HR, 0.67; 95% CI, 0.52–0.87). The benefit on cardiovascular death or hospitalized HF may be greater in patients with a prior history of HF (HR, 0.61; 95% CI, 0.46–0.80) compared with those without HF at baseline (HR, 0.87; 95% CI, 0.72–1.06; P interaction =0.021). The effects of canagliflozin compared with placebo on other cardiovascular outcomes and key safety outcomes were similar in participants with and without HF at baseline (all interaction P values >0.130), except for a possibly reduced absolute rate of events attributable to osmotic diuresis among those with a prior history of HF ($P=0.03$).

CONCLUSIONS: In patients with type 2 diabetes mellitus and an elevated risk of cardiovascular disease, canagliflozin reduced the risk of cardiovascular death or hospitalized HF across a broad range of different patient subgroups. Benefits may be greater in those with a history of HF at baseline.

CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifiers: NCT01032629 and NCT01989754.

Karin Rådholm, MD, PhD*
Gemma Figtree, MBBS, DPhil*
Vlado Perkovic, MBBS, PhD
Scott D. Solomon, MD
Kenneth W. Mahaffey, MD
Dick de Zeeuw, MD, PhD
Greg Fulcher, MD
Terrance D. Barrett, PhD
Wayne Shaw, DSL
Mehul Desai, MD
David R. Matthews, DPhil, BM, BCh
Bruce Neal, MB, ChB, PhD

Clinical Perspective

What Is New?

- The sodium glucose cotransporter 2 inhibitor cana-gliflozin reduced the risk of a range of composite and cause-specific heart failure (HF) outcomes.
- Benefits from canagliflozin may be greater in those with a history of HF.
- There was no evidence that patients with a history of HF were likely to suffer higher rates of adverse events from canagliflozin.

What Are the Clinical Implications?

- Patients with type 2 diabetes mellitus at risk of HF are particularly likely to benefit from treatment with canagliflozin.
- Beneficial effects of canagliflozin on HF outcomes are likely to be accrued on top of other therapies for HF management.

Type 2 diabetes mellitus is associated with a substantial risk of cardiovascular and renal disease, including heart failure (HF).[1–3] HF in diabetes mellitus is attributed to macrovascular and microvascular dysfunction, volume overload, impaired renal function, and direct effects of diabetes mellitus and insulin resistance on cardiac myocytes.[4–7] Mortality outcomes for patients with type 2 diabetes mellitus and HF are worse than for patients with either of the diseases alone, with a median survival of just 4 years.[8] Before the introduction of sodium glucose cotransporter 2 (SGLT2) inhibitors, treatment with glucose-lowering agents has not been shown to reduce HF hospitalization,[9] and there is evidence of increased risks of HF in some trials of dipeptidyl peptidase-4 inhibitors[10,11] and the thiazolidinedione class.[9] Two landmark clinical trials using inhibitors of SGLT2—EMPA-REG OUTCOME[12] and the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)[13]—have demonstrated reductions in the risk of hospitalization for HF, with benefits of empagliflozin reported across a broad range of patient groups.[14] The present analyses explored in further detail the effects of canagliflozin on HF and determined the effects of canagliflozin on a range of efficacy and safety outcomes among CANVAS Program participants with and without a history of HF at baseline.

METHODS

Program Design

The study design, characteristics of participants, and main results of the CANVAS Program have previously been published.[13,15] In brief, the CANVAS Program, comprising the 2 similarly designed and conducted trials, CANVAS and CANVAS-R (CANVAS-Renal), was designed to assess the cardiovascular and renal safety and efficacy of canagliflozin compared with placebo, and also assess how any potential benefits might balance against risks. In total, 667 centers in 30 countries were involved in the 2 trials that were scheduled for joint closeout and analysis when ≥688 cardiovascular events and ≥78 weeks of follow-up had been accrued for the last randomized participant, which occurred in February 2017. A complete list of investigators and committees in the CANVAS Program is provided in the Appendix in the online-only Data Supplement. Data from the CANVAS Program will be made available in the public domain via the Yale University Open Data Access Project (http://yoda.yale.edu/) once the product and relevant indication studied have been approved by regulators in the United States and European Union and the study has been completed for 18 months. The trial protocols and statistical analysis plans were published along with the primary CANVAS Program article.[13]

Participants

Participants included in the CANVAS Program were men and women with type 2 diabetes mellitus (glycohemoglobin ≥7.0% and ≤10.5% and estimated glomerular filtration rate >30 mL/min/1.73 m²). Participants were also required to be either ≥30 years of age with a history of symptomatic atherosclerotic cardiovascular disease or ≥50 years of age with ≥2 risk factors for cardiovascular disease (duration of diabetes mellitus ≥10 years, systolic blood pressure >140 mm Hg while on ≥1 antihypertensive agents, current smoker, documented microalbuminuria or macroalbuminuria, or documented high-density lipoprotein cholesterol <1 mmol/L). Patients with New York Association Class IV HF were excluded. The definition of HF at baseline was based on physician review of the patient's medical history at the first visit, with no requirement for collection of diagnostic biomarkers or the conduct of echocardiography. All participants provided informed consent, and ethics approval was obtained for every center.

Randomization, Treatment, and Follow-Up

After a 2-week, single-blind, placebo run-in period, participants were randomized centrally through an interactive web response system using a computer-generated randomization schedule prepared by the study sponsor using randomly permuted blocks. Participants in CANVAS were assigned in a 1:1:1 ratio to canagliflozin 300 mg, canagliflozin 100 mg, or matching placebo, and participants in CANVAS-R were randomly assigned in a 1:1 ratio to canagliflozin or matching placebo, administered at an initial dose of 100 mg daily with optional uptitration to 300 mg from week 13. Participants and all study and sponsor staff were masked to individual treatment allocations until the completion of the study. Use of other background therapy for glycemic management, treatment of HF, and other risk factor control was according to best practices instituted in line with local guidelines.

Participants were followed after randomization in a face-to-face follow-up that was scheduled for 3 visits in the first

year and at 6-month intervals thereafter, with alternating telephone follow-up between face-to-face assessments. Every follow-up included inquiry about primary and secondary outcome events and serious adverse events. Serum creatinine measurement with estimated glomerular filtration rate was performed at least every 26 weeks in both trials. Participants who prematurely discontinued study treatment continued scheduled follow-up wherever possible, with extensive efforts made to obtain full outcome data for all participants during the final follow-up window that spanned from November 2016 to February 2017.

Outcomes

The primary outcome for these analyses was the composite of cardiovascular death or hospitalized HF. The detailed criteria used to define outcomes are included in the Appendix in the online-only Data Supplement. Cardiovascular death included death resulting from an acute myocardial infarction, sudden cardiac death, death because of HF, death because of stroke, and death because of other cardiovascular causes. Hospitalized HF was an event that required an admission to an inpatient unit or a visit to an emergency department, resulting in a ≥24-hour stay and ≥1 clinical symptoms of worsening HF, ≥2 physical signs of HF and a need for additional or increased therapy, and the absence of other noncardiac etiology or other cardiac etiology that might explain the presentation.

Secondary outcomes were fatal or hospitalized HF, fatal HF, hospitalized HF, the composite of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke), fatal or nonfatal myocardial infarction, fatal or nonfatal stroke, all-cause mortality, and serious decline in kidney function (defined as a composite of 40% reduction in estimated glomerular filtration rate sustained for ≥2 consecutive measures, the need for renal replacement therapy, or death from renal causes). The safety outcomes assessed were all serious adverse events and all adverse events leading to discontinuation, as well as amputation, fracture, osmotic diuresis–related adverse events (according to the Medical Dictionary for Regulatory Activities preferred terms: increase in urine output such as polyuria, pollakiuria, micturition urgency and nocturia, as well as those related to thirst; polydipsia, dry mouth, throat dry, or tongue dry), and volume depletion–related adverse events. End point adjudication committees adjudicated all cardiovascular outcomes, renal outcomes, deaths, and fractures. Fatal HF events were those with HF adjudicated as the proximate cause of death.

Statistical Analysis

Categorical variables were summarized as the number of patients with corresponding percentages, and continuous variables were summarized as the mean and standard deviation. Differences in baseline characteristics between participants with a history of HF compared with participants with no history of HF were evaluated using a χ^2 test for categorical variables, a t test for continuous normally distributed variables, and a Wilcoxon 2-sample test for continuous variables with a skewed distribution (distributions were evaluated using an Anderson–Darling test).

Efficacy analyses were based on the full integrated dataset and the intent-to-treat approach, with the comparison being between all participants assigned to canagliflozin (regardless of dose) and all participants assigned to placebo. Annualized incidence rates per 1000 patient-years of follow-up were calculated for all outcomes in addition to hazard ratios (HRs) and 95% confidence intervals (CIs) determined from Cox regression models that included a trial stratification factor. Absolute risk differences for 1000 patients over 5 years and corresponding 95% CIs were estimated as the differences in the incidence rates between randomized treatment groups using a Poisson regression analysis with an assumption of constant annual event probabilities.[16] On-treatment analysis (based on patients who experienced a safety outcome while on study drug or in ≤30 days of study drug discontinuation) was used for the safety outcomes, except for amputation and fracture, which were assessed using intent-to-treat analyses. For all outcome analyses, we tested the homogeneity of treatment effects across the 2 contributing trials using P values for interactions based on the joint test in the Cox regression models, and the same approach was used for testing comparability of effects across subgroups defined by baseline participant characteristics. There was no formal statistical adjustment for multiple comparisons, and P values were interpreted in light of the many assessments made. Analysis of recurrent hospitalization for HF was assessed with an Andersen–Gill model. Analyses were performed using SAS version 9.2, SAS Enterprise Guide version 7.1, and STATA version 13.1.

RESULTS

There were 10142 patients with type 2 diabetes mellitus in the CANVAS Program, and the mean follow-up time was 188.2 weeks. Mean age was 63.3 years, 35.8% of participants were women, the mean duration of diabetes mellitus was 13.5 years, and 65.6% had a history of cardiovascular disease. In addition, 1461 (14.4%) participants reported a history of HF at baseline. These participants were significantly different from the remaining participants in most aspects of demographics and disease history, in addition to exhibiting greater use of concomitant therapies used for the management of HF, including diuretics, renin angiotensin aldosterone system blockers, and β-blockers, but lower usage of statins and metformin (all $P<0.001$; Table). There were 203 cardiovascular deaths or hospitalized HF events recorded among those participants who reported a history of HF at baseline and 449 among those who did not.

Effects of Canagliflozin on HF Outcomes (Overall and in Patient Subgroups)

Compared with placebo, canagliflozin was associated with significantly lower risks of cardiovascular death or hospitalized HF (HR, 0.78; 95% CI, 0.67–0.91), fatal or hospitalized HF (HR, 0.70; 95% CI, 0.55–0.89), as

Table. Baseline Characteristics of Participants With and Without Heart Failure at Baseline

Variable	Participants With Heart Failure			Participants Without Heart Failure			*P* Value Heart Failure vs No Heart Failure
	Canagliflozin (n=803)	Placebo (n=658)	Total (n=1461)	Canagliflozin (n=4992)	Placebo (n=3689)	Total (n=8681)	
Age, y, mean (SD)	64.1 (8.3)	63.4 (8.3)	63.8 (8.3)	63.1 (8.3)	63.5 (8.2)	63.2 (8.2)	0.025
Female, n (%)	346 (43.1)	302 (45.9)	648 (44.4)	1690 (33.9)	1295 (35.1)	2985 (34.4)	<0.001
Race, n (%)							<0.001
White	741 (92.3)	601 (91.3)	1342 (91.9)	3767 (75.5)	2835 (76.9)	6602 (76.1)	
Asian	19 (2.4)	24 (3.6)	43 (2.9)	758 (15.2)	483 (13.1)	1241 (14.3)	
Black or African American	15 (1.9)	13 (2.0)	28 (1.9)	161 (3.2)	147 (4.0)	308 (3.6)	
Other*	28 (3.5)	20 (3.0)	48 (3.3)	306 (6.1)	224 (6.1)	530 (6.1)	
Current smoker, n (%)	118 (14.7)	112 (17.0)	230 (15.7)	902 (18.1)	674 (18.3)	1576 (18.2)	0.025
History of hypertension, n (%)	766 (95.4)	626 (95.1)	1392 (95.3)	4422 (88.6)	3311 (89.8)	7733 (89.1)	<0.001
Duration of diabetes mellitus, y, mean (SD)§	11.9 (7.9)	12.2 (7.7)	12.0 (7.8)	13.7 (7.7)	13.9 (7.8)	13.8 (7.7)	<0.001‖
Microvascular disease history, n (%)							
Retinopathy	271 (33.7)	242 (36.8)	513 (35.1)	932 (18.7)	684 (18.5)	1616 (18.6)	<0.001
Nephropathy	210 (26.2)	185 (28.1)	395 (27.0)	784 (15.7)	595 (16.1)	1379 (15.9)	<0.001
Neuropathy	412 (51.3)	353 (53.6)	765 (52.4)	1375 (27.5)	970 (26.3)	2345 (27.0)	<0.001
Atherosclerotic vascular disease history, n (%)†							
Coronary	681 (84.8)	529 (80.4)	1210 (82.8)	2553 (51.1)	1958 (53.1)	4511 (52.0)	<0.001
Cerebrovascular	280 (34.9)	216 (32.8)	496 (34.0)	833 (16.7)	629 (17.1)	1462 (16.8)	<0.001
Peripheral	266 (33.1)	223 (33.9)	489 (33.5)	910 (18.2)	714 (19.4)	1624 (18.7)	<0.001
Any	757 (94.3)	608 (92.4)	1365 (93.4)	3370 (67.5)	2589 (70.2)	5959 (68.6)	<0.001
Cardiovascular disease history, n (%)‡	658 (81.9)	516 (78.4)	1174 (80.4)	3098 (62.1)	2384 (64.6)	5482 (63.2)	<0.001
History of atrial fibrillation, n (%)	110 (13.7)	101 (15.4)	211 (14.4)	241 (4.8)	161 (4.4)	402 (4.6)	<0.001
History of amputation, n (%)	16 (2.0)	20 (3.0)	36 (2.5)	120 (2.4)	82 (2.2)	202 (2.3)	0.749
Body mass index, kg/m², mean (SD)§	33.1 (5.9)	33.2 (5.9)	33.2 (5.9)	31.8 (5.9)	31.7 (5.9)	31.8 (5.9)	<0.001‖
Systolic blood pressure, mm Hg, mean (SD)	136.9 (14.9)	136.5 (14.3)	136.7 (14.6)	136.4 (15.9)	137.0 (16.0)	136.6 (15.9)	0.800
Diastolic blood pressure, mm Hg, mean (SD)	79.9 (9.5)	79.3 (9.4)	79.6 (9.4)	77.3 (9.6)	77.5 (9.7)	77.4 (9.7)	<0.001
Glycated hemoglobin, %, mean (SD)	8.4 (1.0)	8.4 (1.0)	8.4 (1.0)	8.2 (0.9)	8.2 (0.9)	8.2 (0.9)	<0.001‖
LDL cholesterol, mmol/L, mean (SD)§	2.6 (1.1)	2.6 (1.1)	2.6 (1.1)	2.2 (0.9)	2.2 (0.9)	2.2 (0.9)	<0.001‖
LDL/HDL cholesterol ratio, mean (SD)§	2.3 (1.0)	2.3 (1.1)	2.3 (1.0)	2.0 (0.9)	2.0 (0.9)	2.0 (0.9)	<0.001‖
Estimated glomerular filtration rate, mL/min/1.73 m², mean (SD)§	72.7 (19.5)	73.3 (19.8)	73.0 (19.6)	77.3 (20.3)	76.7 (21.0)	77.1 (20.6)	<0.001‖
Micro- or macroalbuminuria, n (%)§	263 (33.3)	208 (32.2)	471 (32.8)	1465 (29.6)	1090 (29.9)	2555 (29.7)	0.019
Concomitant drug therapies, n (%)							
Diuretic	488 (60.8)	390 (59.3)	878 (60.1)	2048 (41.0)	1564 (42.4)	3612 (41.6)	<0.001
Loop diuretic	201 (25.0)	178 (27.1)	379 (25.9)	515 (10.3)	414 (11.2)	929 (10.7)	<0.001
Renin-angiotensin-aldosterone system blocker	680 (84.7)	572 (86.9)	1252 (85.7)	3965 (79.4)	2899 (78.6)	6864 (79.1)	<0.001
β-Blocker	566 (70.5)	463 (70.4)	1029 (70.4)	2473 (49.5)	1919 (52.0)	4392 (50.6)	<0.001
Statin	558 (69.5)	448 (68.1)	1006 (68.9)	3772 (75.6)	2822 (76.5)	6594 (76.0)	<0.001
Antithrombotic	680 (84.7)	553 (84.0)	1233 (84.4)	3556 (71.2)	2682 (72.7)	6238 (71.9)	<0.001
Insulin	383 (47.7)	320 (48.6)	703 (48.1)	2507 (50.2)	1885 (51.1)	4392 (50.6)	0.080
Metformin	542 (67.5)	451 (68.5)	993 (68.0)	3905 (78.2)	2927 (79.3)	6832 (78.7)	<0.001
Sulfonylurea	376 (46.8)	287 (43.6)	663 (45.4)	2152 (43.1)	1546 (41.9)	3698 (42.6)	0.047
Thiazolidinedione	14 (1.7)	6 (0.9)	20 (1.4)	293 (5.9)	179 (4.9)	472 (5.4)	<0.001

Table. Continued

Variable	Participants With Heart Failure			Participants Without Heart Failure			P Value Heart Failure vs No Heart Failure
	Canagliflozin (n=803)	Placebo (n=658)	Total (n=1461)	Canagliflozin (n=4992)	Placebo (n=3689)	Total (n=8681)	
Dipeptidyl peptidase-4 inhibitor	56 (7.0)	54 (8.2)	110 (7.5)	641 (12.8)	510 (13.8)	1151 (13.3)	<0.001
Glucagon-like peptide-1 receptor agonist	14 (1.7)	12 (1.8)	26 (1.8)	208 (4.2)	173 (4.7)	381 (4.4)	<0.001

HDL indicates high-density lipoprotein; HF, heart failure; LDL, low-density lipoprotein; and SD, standard deviation.

*Includes American Indian or Alaska Native, Native Hawaiian or other Pacific Islander, multiple races, other races, and unknown race.

†Some participants had ≥1 type of atherosclerotic disease.

‡As defined in the protocol.

§Values for duration of diabetes mellitus categories were calculated based on 5790 patients for canagliflozin, 4341 for placebo, and 10131 for the total population. Values for body mass index categories were calculated based on 5787 patients for canagliflozin, 4341 for placebo, and 10128 for the total population. Values for LDL cholesterol categories were calculated based on 5731 patients for canagliflozin, 4287 for placebo, and 10018 for the total population. Values for estimated glomerular filtration rate categories were calculated based on 5794 patients for canagliflozin, 4346 for placebo, and 10140 for the total population. Values for albuminuria categories were calculated based on 5740 patients for canagliflozin, 4293 for placebo, and 10033 for the total population.

‖Comparison of heart failure versus non–heart failure was analyzed with a Wilcoxon 2-sample test.

well as hospitalized HF alone (HR, 0.67; 95% CI, 0.52–0.87). There was no clear separate effect on fatal HF (HR, 0.89; 95% CI, 0.49–1.60) for which there were few events and wide CIs (Figure 1). A subsidiary analysis of the primary outcome that accounted for competing mortality resulted in an HR estimate of 0.66 (95% CI, 0.51–0.84). The benefit on cardiovascular death or hospitalized HF was borderline significantly (P interaction =0.021) greater in patients with a prior history of HF (HR, 0.61; 95% CI, 0.46–0.80) compared with those without HF at baseline (HR, 0.87; 95% CI, 0.72–1.06; Figure 2). The absolute risk differences were −106.97 (95% CI, −171.59 to −42.34) per 1000 patient-years for participants with a history of HF at baseline and −8.36 (95% CI, −22.08 to 5.36) per 1000 patient-years for participants without a history of HF at baseline (P interaction =0.003).

Rates of HF varied according to baseline characteristics such as age, renal function, and other disease history characteristics, but effects of canagliflozin on cardiovascular death or hospitalized HF were mostly comparable across participant subgroups (Figure 3). Nominally significant interaction was observed with respect to the cardiovascular death or hospitalized HF outcome for several subgroups, including patients with higher versus lower body mass index, lower versus higher baseline glycohemoglobin, with versus without background use of diuretic therapy, and with versus without background metformin use (all P interaction >0.02; Figure 3). Participants randomized to canagliflozin treatment had less recurrent hospitalizations for HF during follow-up compared with participants assigned to placebo (HR, 0.68; 95% CI, 0.47–0.96). In the CANVAS trial, in which participants were assigned at random to placebo, canagliflozin 100 mg, or canagliflozin 300 mg, there was no evidence that the effects on cardiovascular death or hospitalized HF varied by dose (100 mg versus placebo: HR, 0.82; 95% CI, 0.65–1.03; and 300 mg versus placebo: HR, 0.82; 95% CI, 0.65–1.03). Among the subset of participants who reported a history of HF

and loop diuretic use at baseline (n=379), the HR for the primary outcome was 0.54 (95% CI, 0.37–0.78).

Effects of Canagliflozin on Cardiovascular, Kidney, and Death Outcomes in Patients With and Without HF at Baseline

Proportional effects of canagliflozin compared with placebo were comparable in patients with and without HF at baseline for major adverse cardiovascular events, cardiovascular death, myocardial infarction, stroke, all-cause mortality, and serious decline in kidney function (all P interaction >0.160; Figure 2). Patients with a history of HF were at higher absolute risk of most outcomes. Although the numeric values for risk differences were typically greater among participants with a history of HF compared with those without, none reached statistical significance (all P interaction >0.130).

Safety Outcomes

Compared with placebo, canagliflozin has established associations with increased risks of amputation, fracture, and volume depletion, but there was no evidence of proportional differences in these risks between patients with and without HF at baseline (all P interaction >0.160; Figure 4). The absolute risk of osmotic diuresis-related events, another established risk of therapy, was significantly lower in patients with a history of HF compared with those without (P interaction =0.029; Figure 4).

DISCUSSION

Patients with type 2 diabetes mellitus and established cardiovascular disease or at high risk of cardiovascular events who were treated with canagliflozin experienced significantly reduced rates of cardiovascular death or

Figure 1. Effects of canagliflozin on heart failure outcomes.
A through D, Effects of canagliflozin on cardiovascular death or hospitalized heart failure (A), fatal or hospitalized heart failure (B), fatal heart failure (C), and hospitalized heart failure (D). CI indicates confidence interval; and HF, heart failure.

hospitalized HF. Benefits may be greater in those with a history of HF compared with those without. Effects were apparent across a broad range of participant subgroups, including those using established treatments for the prevention of HF, such as blockade of the renin angiotensin aldosterone system, diuretics, and β-blockers.

Other cardiovascular outcomes and death generally occurred more frequently in patients with a history of HF compared with those without, but both sets of participants experienced comparable reductions in the risks of these outcomes with the use of canagliflozin. Labeled adverse effects of canagliflozin on amputation and fracture were comparable among patients with and without HF at baseline, but there were possibly lower absolute risks of adverse events related to osmotic diuresis among patients with HF. There was no statistical evidence that adverse events attributable to volume depletion or acute kidney injury were differentially increased by treatment with canagliflozin in those with HF compared with those without HF, although CIs about estimates were wide.

The benefits for HF outcomes appeared early during follow-up, suggesting a mode of action driven primarily by volume and hemodynamic effects. Reductions in preload and afterload stemming from natriuresis,[14] systemic blood pressure lowering,[17] modification of the intrarenal renin angiotensin axis,[18] and reduction in arterial stiffness[19] may all contribute to the protection afforded. Preservation of renal function and the mitigation of volume overload achieved with SGLT2 inhibition also probably contributed to the observed reduction in HF risk. By contrast, antiatherosclerotic effects of SGLT2 inhibition mediated through effects on glucose, blood pressure, and obesity are unlikely to have played a major role in the large and early benefit observed for this outcome.

There may also be direct positive effects of SGLT2 inhibition on cardiac metabolism that are attributable to a shift from fatty acids to ketone bodies as the substrate for myocardial energy generation. Metabolic studies have shown that the hypertrophied and failing heart uses ketone bodies as an alternate fuel source,[20,21] and increased hepatic neogenesis of ketone bodies is an es-

Figure 2. Proportional and absolute effects of canagliflozin compared with placebo on cardiovascular and renal outcomes in patients with and without a history of heart failure at baseline.
*HR (canagliflozin compared to placebo) and its 95% CI are estimated using a Cox proportional hazard model including treatment as the explanatory variable. The model for CV death is stratified by prior CV disease subgroup and study. The models of renal endpoints are stratified for stage of baseline chronic kidney disease, measured by estimated glomerular filtration rate (<60, ≥60 mL/min/1.73 m²) and by study. †Serious decline in kidney function was defined as a 40% reduction in the estimated glomerular filtration rate, the need for renal replacement therapy, or death from renal causes. ARD indicates absolute risk difference over 5 years; CI, confidence interval; HF, heart failure; and HR, hazard ratio.

tablished effect of SGLT2 inhibitors.[22,23] Enhanced cardiac efficiency may also be facilitated by increased oxygen delivery resulting from SGLT2 inhibitor–associated hemoconcentration.[18] Although the SGLT2 receptor is expressed primarily on the luminal surface of the proximal tubule in the kidney, there has been 1 report of SGLT2 expression in heart tissue.[24]

The findings reported here are strengthened by the rigorous design and conduct of the trial, the prespecification of HF as an outcome of interest, and the careful masked adjudication of all relevant events by an expert committee. Capturing the different modes of HF death as a separate cause-specific outcome is challenging and may underestimate the fatal disease burden attributable to HF. Accordingly, we selected the composite of cardiovascular death and hospitalized HF as the primary outcome because of its clinical relevance while also reporting on other more narrowly defined outcomes incorporating events explicitly defined as HF death. The relatively few primary outcome events recorded limits the capacity to detect effects and makes difficult interpretation of borderline significant findings (eg, the interactions of

canagliflozin treatment and HF prevention with baseline characteristics, such as obesity and use of some drug therapies). Interpretation is further complicated by the overlap in these baseline characteristics across participant subgroups. The limited documentation of HF at baseline, and specifically the absence of systematically collected baseline biomarkers or echocardiography data, meant that the estimated prevalence of established HF was imperfect and there was likely some misclassification of patients according to the presence or absence of HF at baseline. It was also not possible to classify baseline HF according to preservation or reduction in ejection fraction. The low rates of loop diuretic use among patients with HF at baseline suggests that most had nonsevere disease and raises additional uncertainty about the HF diagnoses at baseline in some patients.

The effects on HF observed within the CANVAS Program appear mostly comparable to those reported for the EMPA-REG OUTCOME trial. An exception was the observation of a borderline significant greater proportional risk reduction for individuals with a history of HF at baseline in the CANVAS Program,

	Number of events	Patients per 1000 patient-years			HR (95% CI)	P interaction
		Canagliflozin	Placebo			
Study						
CANVAS	427	16.4	19.9		0.82 (0.67, 0.99)	0.46
CANVAS-R	225	15.9	21.9		0.72 (0.55, 0.94)	
Age						
<65 years	259	10.4	15.5		0.65 (0.51, 0.83)	0.09
≥65 years	393	24.4	27.9		0.87 (0.71, 1.07)	
Region						
North America	161	16.8	18.2		0.87 (0.63, 1.20)	0.69
Central America and South America	56	20.5	25.4		0.84 (0.50, 1.43)	
Europe	247	17.5	23.9		0.74 (0.57, 0.95)	
Rest of world	188	13.8	18.3		0.75 (0.56, 1.01)	
BMI						
<30 kg/m²	211	14.2	14.5		1.01 (0.76, 1.34)	0.03
≥30 kg/m²	439	17.5	25.1		0.68 (0.56, 0.82)	
Blood pressure						
Systolic ≥140 mmHg or diastolic ≥90 mmHg	312	17.1	23.8		0.72 (0.58, 0.91)	0.30
Systolic <140 mmHg and diastolic <90 mmHg	340	15.7	18.3		0.84 (0.68, 1.05)	
Diabetes duration						
≥10 years	495	17.7	22.6		0.79 (0.66, 0.94)	0.74
<10 years	155	12.6	16.6		0.75 (0.54, 1.03)	
Baseline glycated hemoglobin						
<8%	254	15.2	16.1		0.97 (0.75, 1.24)	0.04
≥8%	652	17.1	24.6		0.68 (0.55, 0.83)	
Baseline eGFR						
30-60 mL/min/1.73 m²	226	31.6	41.4		0.75 (0.57, 0.98)	0.41
60-90 mL/min/1.73 m²	325	14.7	16.8		0.86 (0.69, 1.08)	
≥90 mL/min/1.73 m²	101	9.7	14.3		0.65 (0.43, 0.96)	
History of CV disease						
Yes	524	21.0	27.4		0.77 (0.65, 0.92)	0.42
No	128	8.9	9.8		0.83 (0.58, 1.19)	
History of atrial fibrillation						
Yes	113	50.9	72.6		0.72 (0.49, 1.05)	0.47
No	539	14.3	17.9		0.79 (0.66, 0.94)	
Baseline insulin use						
Yes	392	19.7	25.0		0.77 (0.63, 0.94)	0.96
No	260	12.9	16.5		0.80 (0.63, 1.03)	
Baseline metformin use						
Yes	394	13.5	15.4		0.88 (0.72, 1.08)	0.03
No	258	24.8	39.1		0.64 (0.50, 0.82)	
Baseline DPP-4 inhibitor use						
Yes	49	9.8	17.9		0.58 (0.33, 1.04)	0.20
No	603	17.0	21.1		0.80 (0.68, 0.94)	
Baseline thiazolidinedione use						
Yes	25	10.9	9.8		0.99 (0.43, 2.33)	0.55
No	627	16.7	21.5		0.77 (0.66, 0.91)	
Baseline RAAS use						
Yes	548	17.1	21.8		0.78 (0.66, 0.93)	0.93
No	104	13.0	16.8		0.78 (0.53, 1.16)	
Baseline β-blocker use						
Yes	428	19.7	27.8		0.70 (0.58, 0.85)	0.06
No	224	12.6	13.1		0.96 (0.73, 1.26)	
Baseline diuretic use						
Yes	408	22.0	31.7		0.71 (0.58, 0.86)	0.03
No	244	11.9	12.1		0.93 (0.72, 1.21)	
Baseline loop diuretic use						
Yes	231	47.9	69.1		0.72 (0.55, 0.93)	0.18
No	421	12.4	14.3		0.83 (0.68, 1.01)	
Baseline non-loop diuretic use						
Yes	177	13.2	18.1		0.71 (0.53, 0.96)	0.53
No	475	17.7	22.1		0.81 (0.67, 0.97)	

0.25 0.50 1.0 2.0 4.0

← Favors Canagliflozin   Favors Placebo →

Figure 3. Effects on cardiovascular death or hospitalized heart failure in subgroups defined by demographic and disease characteristics.
History of CV disease–yes indicates patients were included on the basis of atherosclerotic cardiovascular disease history, whereas history of CV disease–no indicates patients were included on the basis of risk factors alone. BMI indicates body mass index; CANVAS, Canagliflozin Cardiovascular Assessment Study; CANVAS-R, Canagliflozin Cardiovascular Assessment Study–Renal; CI, confidence interval; CV, cardiovascular; DPP-4, dipeptidyl peptidase-4; eGFR, estimated glomerular filtration rate; HR, hazard ratio; and RAAS, renin angiotensin aldosterone system.

which was not matched by a corresponding finding in the analyses of the EMPA-REG OUTCOME trial. This might reflect the different characteristics of the included populations or the slightly different criteria used to define HF outcomes between the 2 studies. However, the multiple and post hoc analyses of HF done for the CANVAS Program and EMPA-REG OUTCOME had limited statistical power to test for interactions, and the risk of missing real differences or observing spurious chance differences is high.

The CANVAS Program data provide clear evidence of the protective effects of canagliflozin on HF and, in conjunction with EMPA-REG OUTCOME, suggest an important role for SGLT2 inhibitors in the prevention of HF among patients with type 2 diabetes mellitus. Additional data from ongoing trials in diabetes mellitus will further clarify the impact of SGLT2 inhibitors on this major cause of mortality and morbidity[25,26] and confirm or refute hypotheses raised by the CANVAS and EMPA-REG OUTCOME trial findings. A series of

	Patients per 1000 patient-years		HR (95% CI)	P interaction	ARD (95% CI) per 1000 patient-years	P interaction
	Canagliflozin	Placebo				
Serious and nonserious adverse events of interest – CANVAS Program						
All serious adverse events						
History of HF	158.2	196.5	0.82 (0.69, 0.97)	0.17	−191.50 (−341.58, −41.47)	0.11
No history of HF	125.4	137.7	0.96 (0.89, 1.04)		−61.31 (−112.18, −10.44)	
Adverse events leading to discontinuation						
History of HF	39.1	36.1	1.04 (0.75, 1.44)	0.95	−15.16 (−45.52, 75.84)	0.98
No history of HF	35.2	32.4	1.15 (1.00, 1.32)		14.14 (−9.02, 37.29)	
Amputation*						
History of HF	9.8	4.2	2.32 (1.10, 5.51)	0.55	28.04 (4.57, 51.51)	0.23
No history of HF	5.8	3.2	1.90 (1.33, 2.78)		12.82 (5.44, 20.21)	
Fracture*						
History of HF	15.5	12.2	1.18 (0.71, 2.00)	0.97	16.66 (−17.56, 50.89)	0.96
No history of HF	15.4	11.9	1.28 (1.04, 1.57)		17.50 (4.28, 30.73)	
Serious and nonserious adverse events of interest – CANVAS only†						
Osmotic diuresis						
History of HF	22.7	15.0	1.55 (0.65, 3.69)	0.16	38.45 (−37.15, 114.05)	0.03
No history of HF	39.4	13.4	3.00 (2.15, 4.17)		130.06 (98.02, 162.10)	
Volume depletion						
History of HF	21.2	14.9	1.69 (0.67, 4.26)	1.00	31.51 (−42.35, 105.38)	0.81
No history of HF	28.0	19.7	1.44 (1.07, 1.92)		41.40 (9.21, 73.59)	
Acute kidney injury events						
History of HF	1.1	4.2	0.27 (0.02, 2.95)	0.40	−15.24 (−46.30, 15.83)	0.53
No history of HF	3.3	4.2	0.79 (0.40, 1.56)		−4.50 (−17.69, 8.68)	

HR scale: 0.125 0.25 0.50 1.00 2.00 4.00 8.00 — Favors Canagliflozin / Favors Placebo

ARD scale: −400 −300 −200 −100 0 100 200 — Favors Canagliflozin / Favors Placebo

Figure 4. Proportional and absolute effects of canagliflozin compared with placebo on key safety outcome in patients with and without a history of heart failure at baseline.
*Based on ITT dataset, whereas all other analyses based on on-treatment dataset. †For these adverse events, the annualized incidence rates are reported based on the CANVAS study alone through January 7, 2014, because, after this time, only serious adverse events or adverse events leading to discontinuation were collected. In the CANVAS-R study, only serious adverse events or adverse events leading to discontinuation were collected for these events. ARD indicates absolute risk difference over 5 years; CANVAS, Canagliflozin Cardiovascular Assessment Study; ITT, intent-totreat; CANVAS-R, Canagliflozin Cardiovascular Assessment Study–Renal; CI, confidence interval; HF, heart failure; and HR, hazard ratio.

new trials specifically exploring mechanisms and testing effects on HF outcomes among patients without diabetes mellitus[27–30] will also provide further insight into the mode of action by which benefits are achieved. In conclusion, among patients with type 2 diabetes mellitus and an elevated risk of cardiovascular disease, canagliflozin reduced the risk of cardiovascular death or hospitalized HF across a broad range of different patient groups and in addition to concomitant therapies for HF. Benefits may be greater in patients with a baseline history of HF compared with those without a history of HF.

ARTICLE INFORMATION

Correspondence

Gemma Figtree, MBBS, DPhil, Kolling Institute of Medical Research, Royal North Shore Hospital, Pacific Highway, St Leonards, New South Wales, NSW 2065, Australia. E-mail gemma.figtree@sydney.edu.au

Affiliations

Department of Medicine and Health Sciences, Division of Community Medicine, Primary Care, Faculty of Health Sciences, Department of Local Care West, County Council of Östergötland, Linköping University, Sweden (K.R.). The George Institute for Global Health (K.R., V.P., B.N.) and Faculty of Medicine (B.N.), University of New South Wales, Sydney, Australia. Royal North Shore Hospital (G.F., V.P., G.F.) and Charles Perkins Centre (B.N.), University of Sydney, Australia. Harvard Medical School and Brigham and Women's Hospital, Boston, MA (S.D.S.). Department of Medicine, Stanford Center for Clinical Research, Stanford University School of Medicine, CA (K.W.M.). University of Groningen, University Medical Center Groningen, The Netherlands (D.d.Z.). Janssen Research & Development, LLC, Raritan, NJ (T.D.B., W.S., M.D.). Oxford Centre for Diabetes, Endocrinology, and Metabolism, University of Oxford, United Kingdom (D.R.M). Harris Manchester College, University of Oxford, United Kingdom (D.R.M.). Imperial College London, United Kingdom (B.N.).

Acknowledgments

REFERENCES

1. Liyanage T, Ninomiya T, Jha V, Neal B, Patrice HM, Okpechi I, Zhao MH, Lv J, Garg AX, Knight J, Rodgers A, Gallagher M, Kotwal S, Cass A, Perkovic V. Worldwide access to treatment for end-stage kidney disease: a systematic review. *Lancet*. 2015;385:1975–1982. doi: 10.1016/S0140-6736(14)61601-9.

2. Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. *Diabetes Res Clin Pract*. 2011;94:311–321. doi: 10.1161/CIRCULATIONAHA.117.030209.

3. Shah AD, Langenberg C, Rapsomaniki E, Denaxas S, Pujades-Rodriguez M, Gale CP, Deanfield J, Smeeth L, Timmis A, Hemingway H. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people. *Lancet Diabetes Endocrinol*. 2015;3:105–113. doi: 10.1016/S2213-8587(14)70219-0.

4. Lehrke M, Marx N. Diabetes mellitus and heart failure. *Am J Cardiol*. 2017;120(1S):S37–S47. doi: 10.1016/j.amjcard.2017.05.014.

5. Nielsen R, Jorsal A, Iversen P, Tolbod L, Bouchelouche K, Sørensen J, Harms HJ, Flyvbjerg A, Bøtker HE, Wiggers H. Heart failure patients with prediabetes and newly diagnosed diabetes display abnormalities in myocardial metabolism. *J Nucl Cardiol*. 2018;25:169–176. doi: 10.1007/s12350-016-0622-0.

6. Sandesara PB, O'Neal WT, Kelli HM, Samman-Tahhan A, Hammadah M, Quyyumi AA, Sperling LS. The prognostic significance of diabetes and microvascular complications in patients with heart failure with preserved ejection fraction. *Diabetes Care*. 2018;41:150–155. doi: 10.2337/dc17-0755.

7. Damman K, Valente MA, Voors AA, O'Connor CM, van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. *Eur Heart J*. 2014;35:455–469. doi: 10.1093/eurheartj/eht386.

8. Cubbon RM, Adams B, Rajwani A, Mercer BN, Patel PA, Gherardi G, Gale CP, Batin PD, Ajjan R, Kearney L, Wheatcroft SB, Sapsford RJ, Witte KK, Kearney MT. Diabetes mellitus is associated with adverse prognosis in chronic heart failure of ischaemic and non-ischaemic aetiology. *Diab Vasc Dis Res*. 2013;10:330–336. doi: 10.1177/1479164112471064.

9. Fitchett DH, Udell JA, Inzucchi SE. Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes. *Eur J Heart Fail*. 2017;19:43–53. doi: 10.1002/ejhf.633.

10. Monami M, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials. *Nutr Metab Cardiovasc Dis*. 2014;24:689–697. doi: 10.1016/j.numecd.2014.01.017.

11. Rehman MB, Tudrej BV, Soustre J, Buisson M, Archambault P, Pouchain D, Vaillant-Roussel H, Gueyffier F, Faillie JL, Perault-Pochat MC, Cornu C, Boussageon R. Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: meta-analysis of placebo-controlled randomized clinical trials. *Diabetes Metab*. 2017;43:48–58. doi: 10.1016/j.diabet.2016.09.005.

12. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *N Engl J Med*. 2015;373:2117–2128. doi: 10.1056/NEJMoa1504720.

13. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. *N Engl J Med*. 2017;377:644–657. doi: 10.1056/NEJMoa1611925.

14. Fitchett D, Zinman B, Wanner C, Lachin JM, Hantel S, Salsali A, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME® trial investigators. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. *Eur Heart J*. 2016;37:1526–1534. doi: 10.1093/eurheartj/ehv728.

15. Neal B, Perkovic V, Mahaffey KW, Fulcher G, Erondu N, Desai M, Shaw W, Law G, Walton MK, Rosenthal N, de Zeeuw D, Matthews DR; CANVAS Program collaborative group. Optimizing the analysis strategy for the CANVAS Program: a prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trials. *Diabetes Obes Metab*. 2017;19:926–935. doi: 10.1111/dom.12924.

16. Altman DG, Andersen PK. Calculating the number needed to treat for trials where the outcome is time to an event. *BMJ*. 1999;319:1492–1495. doi: https://doi.org/10.1136/bmj.319.7223.1492.

17. Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NS. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. *JAMA*. 2003;289:2534–2544. doi: 10.1001/jama.289.19.2534.

18. Staels B. Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms. *Am J Med*. 2017;130(6S):S30–S39. doi: 10.1016/j.amjmed.2017.04.009.

19. Marti CN, Gheorghiade M, Kalogeropoulos AP, Georgiopoulou VV, Quyyumi AA, Butler J. Endothelial dysfunction, arterial stiffness, and heart failure. *J Am Coll Cardiol*. 2012;60:1455–1469. doi: 10.1016/j.jacc.2011.11.082.

20. Aubert G, Martin OJ, Horton JL, Lai L, Vega RB, Leone TC, Koves T, Gardell SJ, Kruger M, Hoppel CL, Lewandowski ED, Crawford PA, Muoio DM, Kelly DP. The failing heart relies on ketone bodies as a fuel. *Circulation*. 2016;133:698–705. doi: 10.1161/CIRCULATIONAHA.115.017355.

21. Mizuno Y, Harada E, Nakagawa H, Morikawa Y, Shono M, Kugimiya F, Yoshimura M, Yasue H. The diabetic heart utilizes ketone bodies as an energy source. *Metabolism*. 2017;77:65–72. doi: 10.1016/j.metabol.2017.08.005.

22. Ferrannini E, Baldi S, Frascerra S, Astiarraga B, Heise T, Bizzotto R, Mari A, Pieber TR, Muscelli E. Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. *Diabetes*. 2016;65:1190–1195. doi: 10.2337/db15-1356.

23. Kappel BA, Lehrke M, Schütt K, Artati A, Adamski J, Lebherz C, Marx N. Effect of empagliflozin on the metabolic signature of patients with type 2 diabetes mellitus and cardiovascular disease. *Circulation*. 2017;136:969–972. doi: 10.1161/CIRCULATIONAHA.117.029166.

24. Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. *Physiol Rev*. 2011;91:733–794. doi: 10.1152/physrev.00055.2009.

25. Mordi NA, Mordi IR, Singh JS, Baig F, Choy AM, McCrimmon RJ, Struthers AD, Lang CC. Renal and Cardiovascular Effects of Sodium-Glucose Co-

transporter 2 (SGLT2) Inhibition in Combination With Loop Diuretics in Diabetic Patients With Chronic Heart Failure (RECEDE-CHF): protocol for a randomised controlled double-blind cross-over trial. *BMJ Open*. 2017;7:e018097. doi: 10.1136/bmjopen-2017-018097.

26. Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. *Circulation*. 2016;134:752–772. doi: 10.1161/CIRCULATIONAHA.116.021887.

27. Butler J, Hamo CE, Filippatos G, Pocock SJ, Bernstein RA, Brueckmann M, Cheung AK, George JT, Green JB, Januzzi JL, Kaul S, Lam CSP, Lip GYH, Marx N, McCullough PA, Mehta CR, Ponikowski P, Rosenstock J, Sattar N, Salsali A, Scirica BM, Shah SJ, Tsutsui H, Verma S, Wanner C, Woerle HJ, Zannad F, Anker SD; EMPEROR Trials Program. The potential role and ra-

tionale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors. *Eur J Heart Fail*. 2017;19:1390–1400. doi: 10.1002/ejhf.933.

28. National Institutes of Health. EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced). Identifier: NCT03057977. https://www.clinicaltrials.gov. Accessed March 26, 2018.

29. National Institutes of Health. EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved). Identifier: NCT03057951. https://www.clinicaltrials.gov. Accessed March 26, 2018.

30. National Institutes of Health. Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure (Dapa-HF). Identifier: NCT03036124. https://www.clinicaltrials.gov. Accessed March 26, 2018.